Feb 5- A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.. They closed up $2.00, or 19.7 percent, at $12.13 on the Nasdaq. District Judge Renée Marie Bumb in Camden, New Jersey said Allergan's proposed generic infringed two of the three Supernus...» Read More
Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.
Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.
Overpaying for our prescription drugs just feels like a headache no one needs right now, doesn’t it?
Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.
Despite my repeated invitations for his first post-jailhouse interview on this blog and through one of his contacts, Sam Waksal didn't respond. Given his Manhattan social scene background it should not, perhaps, come as a surprise that the founder of ImClone Systems decided to have his coming-out party in "New York" magazine.
The overwhelming majority of people who have voted in the “Pharma’s Market” poll about the future of Genentech’s execs and top scientists thinks most of them will eventually bolt.
Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.
All of a sudden yesterday and today shares of Dendreon —my favorite biotech story—shot up on heavy volume.
Even when picking stocks, cash is king, according to Wouter Weijand from Fortis Investments, who likes US funeral service company Hillenbrand, Swiss healthcare manufacturer Novartis, and Australia’s ANZ Bank.
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.
Anyone out there who sees hope in the stock market must be on drugs. And I am: Lipitor and Novasc from Pfizer, Vasotec from Merck, and four other pills, all of which I gobble every day to stop myself from blowing a gasket. So let me say, with some personal pill-popping experience, that this may be a great time to buy drug stocks.
Even better: Events that could push the Dow up another 1,000 points.
Plus, Cramer makes the call on Goldman Sachs, General Electric, Apple, Citigroup and more.
Only on a day like today when it's wall-to-wall Madoff coverage would a $47 billion deal, the second $40-billion-plus deal to be done in four days, struggle to get some airtime.
When a press release crosses the wires or pops into the inbox from a Dow component announcing positive late-stage test results on a cancer drug, you rush to get the headlines on the air as quickly as possible.
The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.
On my Thomson Reuters screen I have the stock quotes of a few dozen of the biopharma companies I cover. Lately, when I glance over at it, there's been a lot of red. With today's market rally, there's a whole lotta green. And that's why the quote in red for Genentech kind of sticks out like a sore thumb.
They may have the same name, but America's oldest teenager Dick Clark and Merck's Chairman and CEO Dick Clark appear to have little else in common. One loves the camera, the other not so much.
With cash scarce, credit tight and big drug companies intent on branching into biotechnology themselves, struggling bio-tech start-ups may no longer get second and third chances to succeed from thier investors, the New York Times reports.
New Jersey, where I live and work, is known as "The World's Medicine Chest" or "The Silicon Valley of Pharma."